Trial Profile
Determination of the concentration of Teriflunomide in serum and cerebrospinal fluid from patients with multiple sclerosis who are treated with Teriflunomide 14 mg daily.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Feb 2023
Price :
$35
*
At a glance
- Drugs Teriflunomide (Primary)
- Indications Multiple sclerosis
- Focus Pharmacokinetics
- 02 Feb 2023 Results assessing to determine the passage of teriflunomide over the blood-cerebrospinal fluid barrier (BCSFB) published in the CNS Drugs
- 09 Dec 2022 Status changed from recruiting to completed.
- 16 Mar 2021 Planned primary completion date changed from 31 Dec 2020 to 31 Mar 2021.